Declaration of interests
MKK has served as a consultant for Phamacotherapies for Alcohol and Substance Use Disorders Alliance and Guidepoint. AFJ has received an unrestricted grant from Novo Nordisk to investigate the effects of semaglutide on metabolic disturbances in participants with schizophrenia treated with antipsychotics; serves on a RCT advisory panel for Novo Nordisk, receiving no honorarium; and has served as a consultant for Phamacotherapies for Alcohol and Substance Use Disorders Alliance and Guidepoint. TV has served on scientific advisory panels and been part of speakers bureaus for Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mundipharma, Novo Nordisk, Carmot/Roche, Sanofi, Sun Pharmaceuticals, and Zealand Pharma; and served as a consultant for Amgen, Astra-Zeneca, BMS, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mundipharma, Novo Nordisk, Carmot/Roche, Sanofi, Sun Pharmaceuticals, and Zealand Pharma. JJH has received a grant from the Novo Nordisk Foundation to the Center for Basic Metabolic Research at Copenhagen University (NNF23SA0084103); has given lectures and received travel support from AstraZeneca, Eli Lilly, and Decheng Capital Global Lifesciences Fund; has served as a consultant for Third Bridge, Metaphor Biotechnologies, Vial Health Technology, Crinetics Pharmaceuticals, Immunic Therapeutics, Guidepoint, Fractyl Health, Alcimed, Soffinova Partners, and Jefferies International; has received support for attending meetings and/or travel from the Endocrine Society and Eli Lilly; participates on an advisory board for Novo Nordisk; is a cofounder and board member of Antag Therapeutics and Bainan Biotech, and sits on the boards of both, unpaid; and has stock options with Antag Therapeutics. All other authors declare no competing interests.
